Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Colorcon
Mallinckrodt
McKesson
Moodys

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR INVEGA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Invega

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00330863 ↗ Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy Completed National Institute of Mental Health (NIMH) Phase 4 2006-05-01 This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
NCT00330863 ↗ Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy Completed Northwell Health Phase 4 2006-05-01 This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
NCT00488891 ↗ The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia Terminated Ortho-McNeil Janssen Scientific Affairs, LLC 2007-04-01 The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release (ER) or another oral atypical antipsychotic agent (AAP) including aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone.
NCT00549562 ↗ Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed Ortho-McNeil Janssen Scientific Affairs, LLC Phase 3 2007-11-01 This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Invega

Condition Name

Condition Name for Invega
Intervention Trials
Schizophrenia 17
Schizoaffective Disorder 5
Bipolar Disorder 2
Methamphetamine Dependence 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Invega
Intervention Trials
Schizophrenia 19
Disease 8
Psychotic Disorders 7
Bipolar Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Invega

Trials by Country

Trials by Country for Invega
Location Trials
United States 49
Germany 5
Korea, Republic of 4
Spain 4
Poland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Invega
Location Trials
California 7
New Jersey 4
Massachusetts 3
Georgia 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Invega

Clinical Trial Phase

Clinical Trial Phase for Invega
Clinical Trial Phase Trials
Phase 4 16
Phase 3 4
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Invega
Clinical Trial Phase Trials
Completed 19
Terminated 3
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Invega

Sponsor Name

Sponsor Name for Invega
Sponsor Trials
Janssen Korea, Ltd., Korea 3
Ortho-McNeil Janssen Scientific Affairs, LLC 3
Luye Pharma Group Ltd. 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Invega
Sponsor Trials
Other 24
Industry 24
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Express Scripts
Boehringer Ingelheim
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.